Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.47 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL720924 | 0.95 | TLR2 (0.43) | EPHX2P2RY10GPR34 | |
| Hydrochloric Acid SCHEMBL719150 | 0.86 | MAPT (0.48) | P2RY10GPR34 | |
| Hydrochloric Acid SCHEMBL716105 | 0.85 | MAPT (0.47) | P2RY10GPR34 | |
| Hydrochloric Acid SCHEMBL719757 | 0.83 | DGKA (0.50) | P2RY10GPR34 | |
| SCHEMBL16172027 | 0.83 | GNAI3 (0.43) | EPHX2 | |
| SCHEMBL15026961 | 0.82 | GNAI3 (0.42) | EPHX2P2RY10 | |
| Oleic Acid SCHEMBL28613740 | 0.81 | EPHX2 (0.54) | EPHX2 | |
| Nervonic Acid SCHEMBL20694895 | 0.81 | EPHX2 (0.57) | EPHX2 | |
| Oleic Acid SCHEMBL1287108 | 0.81 | EPHX2 (0.57) | EPHX2 | |
| Oleic Acid SCHEMBL1736035 | 0.81 | EPHX2 (0.57) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4175967-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022006368-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2022-01-06 | — | — | WO | claimed |
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2021-04-06 | — | — | US | claimed |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2018-12-18 | — | — | US | claimed |
| US-20170029448-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2017-02-02 | — | — | US | claimed |
| US-7915230-B2 | Reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | claimed |
| EP-2015780-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2009-01-21 | — | — | EP | claimed |
| WO-2007130073-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12037600-B2 | Transfection complexes and methods of using the same | MOLECULAR TRANSFER, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240209390-A1 | PLANT VIRUS MOVEMENT PROTEINS AND METHODS OF USING SAME | MOLECULAR TRANSFER, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | disclosed |
| EP-2015780-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007130073-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-6458381-B1 | COMPLEXING LYSINE-BIS-(O,O*-9-OCTADECENOYL-B-HYDROXYETHYL) AMIDE WITH LIPID, RNA, DNA, OR POLYPEPTIDE | Sourovoi, Andrej (RU) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | EPHX2 3351/4885P2RY10 4070/4885GPR34 4145/4885 |
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | EPHX2 3351/4885P2RY10 4070/4885GPR34 4145/4885 |
| US-20240209390-A1 | PLANT VIRUS MOVEMENT PROTEINS AND METHODS OF USING SAME | HDLBP, PHAX, PLTP | EPHX2 3937/4885P2RY10 3743/4885GPR34 3968/4885 |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | EPHX2 2852/4885P2RY10 3648/4885GPR34 4137/4885 |
| US-20170029448-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | PHOSPHO1, PLTP, MBOAT7 | EPHX2 2141/4885P2RY10 2501/4885GPR34 4245/4885 |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | FUS, PHAX, PICALM | EPHX2 4292/4885P2RY10 4573/4885GPR34 4295/4885 |
| US-12037600-B2 | Transfection complexes and methods of using the same | TIAL1, NPC1L1, LIPA | EPHX2 2692/4885P2RY10 2429/4885GPR34 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.